SUPPLEMENTAL TABLES

S1. Difference in medical therapy between those with normal and abnormal vasoreactivity variables			
Baseline Medications	**Coronary Flow Reserve**		
	CFR ≥ 2.32 (n=122)	**CFR < 2.32 (n=77)**	**Fisher's Exact Test p-value**
ACE-I/ARB	30 (25%)	20 (26%)	0.87
Beta Blockers	32 (26%)	28 (36%)	0.15
Ca Antagonists	30 (25%)	23 (30%)	0.42
Nitrates	25 (20%)	17 (22%)	0.86
Statins	18 (15%)	15 (19%)	0.44
Aspirin	57 (47%)	42 (55%)	0.31
Diuretics	26 (21%)	20 (26%)	0.49
Vasodilators	9 (7%)	3 (4%)	0.38
Baseline Medications	**Coronary Blood Flow**		
	CBF ≥ 50 (n=58)	**CBF < 50 (n=54)**	**Fisher's Exact Test p-value**
ACE-I/ARB	15 (26%)	17 (31%)	0.54
Beta Blockers	12 (21%)	20 (37%)	0.063
Ca Antagonists	18 (31%)	16 (30%)	1
Nitrates	10 (17%)	11 (20%)	0.81
Statins	8 (14%)	15 (28%)	0.10
Aspirin	23 (40%)	31 (57%)	0.09
Diuretics	11 (19%)	16 (30%)	0.27
Vasodilators	5 (9%)	1 (2%)	0.21
Baseline Medications	**Change in coronary surface area in response to acetylcholine**		
	ACH > 0 (n=56)	**ACH ≤ 0 (n=69)**	**Fisher's Exact Test p-value**
ACE-I/ARB	10 (18%)	23 (33%)	0.066

Beta Blockers	15 (27%)	18 (26%)	1
Ca Antagonists	16 (29%)	20 (29%)	1
Nitrates	8 (14%)	16 (23%)	0.26
Statins	9 (16%)	17 (25%)	0.27
Aspirin	22 (39%)	37 (54%)	0.11
Diuretics	11 (20%)	15 (22%)	0.83
Vasodilators	2 (4%)	6 (9%)	0.29
Baseline Medications	**Change in coronary surface area in response to nitroglycerine**		
	NTG > 20 (n=55)	**NTG ≤ 20 (n=75)**	**Fisher's Exact Test p-value**
ACE-I/ARB	11 (20%)	24 (32%)	0.16
Beta Blockers	19 (35%)	17 (23%)	0.17
Ca Antagonists	16 (29%)	24 (32%)	0.85
Nitrates	11 (20%)	16 (21%)	1
Statins	10 (18%)	16 (21%)	0.82
Aspirin	24 (44%)	39 (53%)	0.37
Diuretics	12 (22%)	13 (17%)	0.65
Vasodilators	2 (4%)	6 (8%)	0.47

S2. Difference in medical therapy between those with events and no events

Medications	NO event, n=181 possible	Event (Death, MI, stroke, HF), n=43 possible	log rank P value
ACE-I/ARB	42 (23%)	12 (28%)	0.6
Beta Blockers	48 (27%)	17 (40%)	0.08
Calcium channel blockers	42 (23%)	16 (37%)	**0.047**
Nitrates	32 (18%)	15 (35%)	**0.004**
Statins	24 (13%)	14 (33%)	**0.003**
Aspirin	85 (47%)	25 (28%)	0.25

S3. Difference in medical therapy between those with events and no events stratified by the presence of obstructive CAD

Medications	Obstructive CAD			Non-Obstructive CAD		
	No event, n=30	Event (Death, MI, stroke, HF), n=13	log rank P value	No Event, n=149	Event (Death, MI, stroke, HF), n=30	log rank P value
ACE-I/ARB	12 (40%)	8 (62%)	0.3244	29 (19%)	4 (13%)	0.4027
Beta Blockers	11 (37%)	9 (69%)	0.0897	37 (25%)	8 (27%)	0.6914
Calcium channel blockers	8 (27%)	4 (31%)	0.7232	34 (23%)	12 (40%)	**0.0362**
Nitrates	9 (30%)	7 (54%)	0.2364	23 (15%)	8 (27%)	**0.0384**
Statins	6 (20%)	6 (46%)	0.1866	18 (12%)	8 (27%)	**0.0272**
Aspirin	26 (87%)	8 (62%)	0.0768	58 (39%)	17 (57%)	0.1010